Key result
Clarithromycin co-administration with simvastatin triggers severe rhabdomyolysis via CYP3A4 inhibition.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Rhabdomyolysis is a well-documented side effect of statin therapy. This risk is increased with concurrent use of medications that inhibit cytochrome p450-3A4 (CYP3A4), such as macrolide antibiotics. We present the case of a 67-year-old patient who was commenced on clarithromycin on a background of simvastatin therapy, resulting in rhabdomyolysis. This case highlights the need for awareness of common drug interactions associated with statins. It also emphasizes the significance of commencing statins at a lower dose in new patients, and lastly, the importance of early recognition and management of rhabdomyolysis to prevent the development of complications.
No takes yet. Share an insight, caveat, or question.
Ezad et al. (2018) conducted a case report in Statin-induced rhabdomyolysis (n=1). Concurrent use of clarithromycin and simvastatin was evaluated on Rhabdomyolysis. Concurrent use of clarithromycin and simvastatin in a 67-year-old patient resulted in rhabdomyolysis, highlighting the risk of CYP3A4 inhibitor interactions with statins.
Synapse has enriched 10 related papers. Consider them for comparative context: